Navigation Links
Magellan Biosciences Sells its Life Sciences Tools Business to Dionex

CHELMSFORD, Mass., Sept. 22 /PRNewswire/ -- Magellan Biosciences, Inc. (Magellan), an emerging leader in clinical diagnostics, has sold its ESA Life Sciences Tools (LST) business to Sunnyvale, California-based Dionex, Inc. (Nasdaq: DNEX). The sale includes all of ESA's HPLC-related products, HPLC clinical assays, the ESA Laboratories services and assets, as well as ESA's headquarters in Chelmsford, Massachusetts. Financial terms of the transaction were not disclosed.

"This sale enables Magellan to concentrate on our clinical-diagnostic customers. We can now apply all of our resources to developing and supporting innovation in diagnostic products that give clinicians the answers they need to make more-informed treatment decisions for superior, outcomes-based care," said Magellan President and Chief Executive Officer, Robert J. Rosenthal, Ph.D. "Stay tuned. Over the next several months we will be highlighting the new diagnostics-focused Magellan. In the meantime, customers can continue to count on the Magellan brands and people they've come to know: LeadCare((R) )for( )blood-lead-testing systems, Dynex((R)) for automated ELISA processing systems, and TREK for microbiology."

LeadCare - Because traditional prescription-based and send-out practices have missed those children most at-risk for lead poisoning, policy-makers at the federal, state, and local level are taking action to encourage the use of the LeadCare II system to ensure that children receive mandated testing. For example, New York State Medicaid just began reimbursing doctors and health clinics for LeadCare II tests. As a CLIA-waived test, the LeadCare II system removes all the complications formerly associated with blood-lead testing - waiting days for lab results, spending precious staff time and resources trying to contact patients for critical follow-up care, or tracking down results for record-keeping, reporting, or compliance purposes. Visit to learn more. For important lead-poisoning prevention resources, links to consumer product recall information, and tips for keeping children safe, visit

Dynex - The DS2(R) two-plate and DSX(R) four-plate ELISA processing systems are designed for efficiency and reliability with the 'expert' inside. They perform the most-sophisticated analyses, but are easy to use for operators with varying levels of education and experience. The DSX and DS2 are open systems with full walk-away automation and precise liquid-handling capabilities. They execute the entire complement of analytical steps required for virtually any ELISA immunoassay: adding samples and reagents, washing, incubation, and detection, delivering all you need to ensure the rigorous, repeatable analyses required in critical applications - from immunology to infectious disease, hormone, allergy, blood-chemistry, and drugs-of-abuse testing. To see a video of the DS2 at work, visit

TREK - The award-winning VersaTREK(R) automated microbial-detection system performs four tests on one automated platform: culture for blood, sterile body fluids, and mycobacteria detection, as well as Mycobacterium tuberculosis (TB) susceptibility testing. TREK's signature Sensititre(R) product line for susceptibility and identification testing enables labs to test - on a single cost-effective, LIS-compatible system - more FDA-cleared antimicrobial drugs than on any other automated platform against the widest range of non-fastidious and fastidious bacteria and yeasts. This saves microbiology labs from having to use multiple off-line test procedures to obtain accurate susceptibility data. TREK's platform is the system-of-choice for global surveillance initiatives, including NARMS (National Antimicrobial Resistance Monitoring System). For more information on TREK products, visit

About Magellan (

An emerging leader in clinical-diagnostic markets for near-patient testing, hospital-based labs, and microbiology, Magellan serves customers worldwide with rapid point-of-care analyzers and consumables; blood culture, antimicrobic-susceptibility tests, systems, and reagents; as well as automated ELISA processing systems, microplate instrumentation, and associated consumables. We design all our products to deliver better, faster, more-reliable diagnostic results to help doctors make more-informed treatment decisions and improve health outcomes. Magellan brands include LeadCare, Dynex, and TREK.

SOURCE Magellan Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
2. Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo
3. Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System
4. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
5. Cell Biosciences Launches Unique Protein Phosphorylation Assay Service
6. Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences(R) to Provide World-Class Fluid Management and Liquid/Powder System Solutions
7. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
8. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
9. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
10. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
11. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Post Your Comments:
(Date:11/25/2015)... ... , ... For the first time, Vitalalert is donating half of its earnings ... partnership between the two groups began in 2014 with Vitalalert pledging a portion of ... was founded in 1954 and is an international Christian-based health organization whose mission is ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology: